Lapatinib
Spezifikationen
231277-92-2CAS-Nummer
878-720-7EG-Nummer
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amineIUPAC-Name
C29H26ClFN4O4SChemische Formel
581.1 g/molMolekulargewicht
Lapatinib; 231277-92-2; GW572016; GW 572016; GSK 572016; GW-572016; DTXSID7046675; n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine; GSK572016; GSK-572016; 0VUA21238F; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; GW-572016X; DTXCID5026675; CHEBI:49603; GW2016; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; lapatinibum; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-methanesulfonylethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; RefChem:798502; L01XE07; GW 2016; GW-282974X; 878-720-7; N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-quinazolinamine; NSC727989; Tykerb; Lapatinib [INN]; Lapatinib free base; Lapatinib (free base); Lapatanib; Lapatinib base; C29H26ClFN4O4S; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; Lapatinib (INN); MFCD09264194; FMM; N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; 1210608-87-9; N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; CHEMBL554; Lapatinib (GW572016); NSC745750; s2111; NCGC00167507-01; GW 282974X; GW-2016; 913989-15-8; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; CAS-231277-92-2; Lapatinib [INN:BAN]; 231277-92-2 (free base); L0360; UNII-0VUA21238F; Lapatinib?; Tykerb;; HSDB 8209; 1xkk; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; Lapatinib ditosylate?; Lapatinib (Standard); Lapatinib, Free base; nchembio866-comp20; Kinome_3684; Kinome_3685; LAPATINIB [MI]; LAPATINIB [VANDF]; LAPATINIB [WHO-DD]; SCHEMBL8100; LAPATINIB [EMA EPAR]; BDBM5445; cid_208908; GTPL5692; orb1225581; orb1310962; orb3141254; SCHEMBL29351024; SCHEMBL29464189; BDBM32368; EX-A402; BCFGMOOMADDAQU-UHFFFAOYSA-N; GLXC-06463; HMS2089H10; HMS3244N06; HMS3244N10; HMS3244N14; HMS3744K11; HMS5080G12; Tykerb (TN) (Glaxo Smith Kline); Lapatinib base - Bio-X trade mark; LAPATINIB (GW-572016); Tox21_112505; EBC-00694; HY-50898R; NSC800780; AKOS005145766; Tox21_112505_1; AC-1314; CCG-270133; DB01259; FC12433; NSC-745750; NSC-800780; SB16918; SDCCGSBI-0634417.P003; NCGC00167507-02; NCGC00167507-03; NCGC00167507-04; NCGC00167507-09; NCGC00167507-17; NCGC00167507-18; AS-14065; BC164610; BP-43661; HY-50898; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; NS00003012; SW199101-5; D08108; EN300-117254; AB01273965-01; AB01273965-02; AB01273965-03; AB01273965_04; AB01273965_05; Q420323; SR-05000001472-1; BRD-K19687926-001-01-7; BRD-K19687926-001-04-1; BRD-K19687926-001-10-8; BRD-K19687926-379-02-5; BRD-K19687926-379-07-4; 1092929-10-6; LAPATINIB FREE BASETYKERBLAPATINIBGW 572016N-(3-CHLORO-4-{[(3-FLUOROPHENYL)METHYL]OXY}PHENYL)-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE; N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine; N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamineSynonyme
Produkte, die Lapatinib enthalten
Unternehmen, die Lapatinib verkaufen
JM
Jiangsu Magic Biotechnology Co., LtdChinaSI
Sinoway Industrial Co.Ltd.ChinaHH
HANGZHOU HONGQIN PHARMTECH CO.,LTDChinaSS
Shanghai Sunway Pharmaceutical Technoiogy Co.,LtdChinaBE
BEIJING EARLYBIRD INDUSTRY DEVELOPMENT CO.,LTD.China
NE
Novartis Europharm LimitedSpain
AC
AFINE CHEMICALS LIMITED